To develop an ideal blood clot imaging and targeting agent, a single-chain antibody (SCA) fragment based on a fibrin-specific monoclonal antibody, MH-1, was constructed and produced via secretion from Bacillus subtilis. Through a systematic study involving a series of B. subtilis strains, insufficient intracellular and extracytoplasmic molecular chaperones and high sensitivity to wall-bound protease (WprA) were believed to be the major factors that lead to poor production of MH-1 SCA. Intracellular and extracytoplasmic molecular chaperones apparently act in a sequential manner. The combination of enhanced coproduction of both molecular chaperones and wprA inactivation leads to the development of an engineered B. subtilis strain, WB800HM[pEPP]. This strain allows secretory production of MH-1 SCA at a level of 10 to 15 mg/liter. In contrast, with WB700N (a seven-extracellular-protease-deficient strain) as the host, no MH-1 SCA could be detected in both secreted and cellular fractions. Secreted MH-1 SCA from WB800HM[pMH1, pEPP] could be affinity purified using a protein L matrix. It retains comparable affinity and specificity as the parental MH-1 monoclonal antibody. This expression system can potentially be applied to produce other single-chain antibody fragments, especially those with folding and protease sensitivity problems.
Fibrin-specific monoclonal antibodies (MAbs) have many practical applications. Since the presence of soluble fibrin in serum is an early indicator of blood clot formation in many thrombotic events, including pulmonary embolism as well as deep venous thrombosis and disseminated intravascular coagulopathy, enzyme-linked immunosorbent assay (ELISA) systems have been developed based on fibrin-specific MAbs as a diagnostic tool to detect these thrombotic disorders (6, 13) . Fibrin-specific antibodies also serve as noninvasive imaging agents to locate blood clots and as fibrin targeting agents to deliver blood clot-dissolving agents selectively to the clots (16, 33, 41, 47) . For these applications, it would be important to miniaturize intact MAbs (ϳ160 kDa) to single-chain antibody fragments (SCA; ϳ25 kDa) which retain an intact antigen binding site (7, 19) . With a short in vivo half-life, SCA fragments are better suited as imaging agents since excess labeled SCA fragments can be rapidly eliminated from the circulation (8) (9) (10) 38 ). This feature is essential for decreasing the background to the basal level in a short period of time. As targeting agents, fibrin-specific SCA fragments are expected to have better clot penetration capability and would be ideal to serve as targeting domains when fused to clot-dissolving agents. Although several fibrin-specific MAbs have been generated and characterized, many of them suffer from one or more drawbacks, including low affinity to fibrin, binding to fibrin degradation products, variability in reacting with antigens, and recognition of transiently available neoantigens on fibrin (35, 39, 42, 54) . Gargan et al. (14) reported the development of a fibrin-specific MAb designated MH-1 with a number of desirable features for imaging and targeting applications. MH-1 binds specifically to fibrin with high affinity (K d ϭ 6.7 ϫ 10 Ϫ10 M), even in the presence of a 500-fold molar excess of fibrinogen, and does not react with any fibrin or fibrinogen degradation products.
Production of MH-1 SCA in microbial systems, however, represents a major challenge. It has a strong tendency to form inclusion bodies when expressed in Escherichia coli either intracellularly or via secretion (J. A. McLinden, personal communication). In a previous study using the Bacillus subtilis expression-secretion system, we also encountered the problem of inclusion body formation when we attempted to produce an anti-digoxin SCA (49, 51, 53) . We solved the problem by using an engineered B. subtilis strain (53) which coproduces two series of major intracellular molecular chaperones, including GroES/GroEL and DnaK/DnaJ/GrpE, and an extracytoplasmic molecular chaperone, PrSA (24, 25, 46) . It would be of interest to determine whether B. subtilis would be a better expression host for producing MH-1 SCA. In this study, we report the construction of engineered B. subtilis strains to successfully produce functional MH-1 SCA fragments via secretion. These strains address two major problems associated with the MH-1 SCA production (namely, slow or improper folding and degradation). The resulting MH-1 SCA fragments were affinity purified and demonstrated to retain specificity and affinity comparable to those of the parental MH-1 MAb.
MATERIALS AND METHODS
Construction of pMH-1. Plasmid pMH-1 is a pWB980 derivative (50) carrying a structural gene encoding the MH-1 SCA fragment for secretory production in B. subtilis. The coding sequences of V L and V H were PCR amplified individually as an EcoRI-SacI fragment (forward primer, 5Ј GGG AATTCAAGCTTTTGCAGATATCGTGTTAACACAGTCTCCAGCTTCT TTGG 3Ј; backward primer, 5Ј GAGAGCTCTTAAGATCTCGAGCTTGG TGCCTCCACCGAAC 3Ј) and a BamHI-SphI fragment (forward primer, 5Ј GTGGATCCCAAGTTCAGCTGCAGCAGTCAGGACCTGAG 3Ј; backward primer, 5Ј GTGCATGCTTATGTCGACACGGTTACCGAGGTTCCT TGACCCC 3Ј) by using plasmid pTF77-7A1#46 (kindly provided by James McLinden, American Biogenetic Sciences, Inc.) as the template. Plasmid pTF77-7A1#46 is an E. coli pKK233 derivative carrying a structural gene of MH-1 SCA for expression in E. coli (Fig. 1) . Two PCR primers were designed to generate the linker sequence encoding for a 19-amino acid linker. The 3Ј end region of the forward primer (5Ј GTGAGCTCCTAATGGCGCATCTG AATCTGGATCTGCACCTG 3Ј) is complementary to the 3Ј end region of the backward primer (5Ј GAGGATCCAGGCGCCGAAGACGTGTCAGG TGCAGATCCAGATTCAG 3Ј). The annealed primers were extended to full length by a single cycle of PCR to generate a SacI-BamHI fragment. To assemble the structural gene for the MH-1 SCA, each of these V H , linker, and V L sequences was digested with the corresponding pair of restriction enzymes and sequentially inserted into the polylinker region in the E. coli Bluescript vector (pBS). In the first step, the PCR amplified V H fragment was digested with BamHI and SphI and was inserted to the BamHI-and SphI-digested pBS to generate pBS-V H . This vector was then digested with SacI and BamHI and ligated with the SacI-and BamHI-digested linker fragment. The resulting vector was designated pBS-L-V H . Insertion of the EcoRI-and SacI-digested V L fragment to pBS-L-V H generated pBS-MH1 (Fig. 1) . The assembled structural gene for the MH-1 SCA was digested from pBS-MH1 with HindIII and SphI and ligated to the B. subtilis secretion vector pWB980 digested with the same pair of restriction enzymes. The resulting plasmid was designated pMH-1 (Fig. 1) .
Construction of WB700N, WB700NHM, WB800, and WB800HM. WB700H is a seven-extracellular-protease-deficient B. subtilis strain (55) . Its chromosomal copy of the vpr protease gene was replaced by a modified vpr gene carrying both an internal deletion and the insertion of a hygromycin resistance marker (Table  1) . In order to allow the reuse of the hygromycin marker for the disruption of other protease genes in WB700H, a new WB700 strain, designated WB700N (N stands for a new version), was constructed. WB700N carries an internally deleted vpr gene without the insertion of any antibiotic resistance marker (Table 1) . This strain was constructed by cotransformation of two plasmids, pE194 and a SphIlinearized p⌬VPRBAM (55) , to WB700H. Plasmid p⌬VPRBAM is an E. coli Bluescript vector carrying a modified vpr gene with an internal deletion and the insertion of a BamHI linker at the site of the internal deletion. Transformants were first selected on erythromycin-lincomycin-containing agar plates (5 g of erythromycin/ml and 5 g of lincomycin/ml). They were then checked for the loss of hygromycin resistance by spotting individual colonies to a hygromycin-containing agar plate (100 g of hygromycin/ml). Those transformants that were unable to grow on hygromycin plates were confirmed to carry an internally deleted vpr gene by PCR amplification with a pair of vpr primers. To eliminate the pE194 plasmid in these cells, cells were cultivated at 42°C because of the inability of pE194 to replicate at high temperatures. After this treatment, a majority of the cells were unable to grow on erythromycin-lincomycin-containing agar plates. One of these colonies was designated WB700N. To construct WB700NHM, a B. subtilis strain that coproduces intracellular molecular chaperones from both groE and dnaK operons without heat shock, WB700N was transformed with a KpnI-linearized integration vector pKS3 (51) . This vector is an E. coli Bluescript vector which carries an internally truncated hrcA gene with the insertion of a gentamicin resistance marker at the site of deletion. The KpnI site used for plasmid linearization is located in the polylinker region of the Bluescript vector and is outside of the modified hrcA gene. hrcA encodes a repressor that reduces the expression of both groE and dnaK operons under non-heat shock conditions (56) . One of the resulting gentamicin-resistant transformants was designated WB700NHM ( Table 1 ). The replacement of the natural chromosomal hrcA gene in WB700N by the modified hrcA gene was confirmed by PCR amplification with hrcA-specific primers and the overproduction of GroEL and DnaK in a constitutive manner without heat shock. This WB700NHM strain was used for expression studies. WB800 (Table 1) was constructed by the inactivation of the wall-bound protease gene, wprA (30) , in the genetic background of WB700N. To disrupt the chromosomal wprA gene, an integration vector, p⌬WPRA, was constructed. This is a derivative of the E. coli Bluescript plasmid pBS. A 3.1-kb KpnI-BamHI fragment with the 2.7-kb wprA gene at the central portion of the fragment was generated by PCR using a pair of primers (WPRF, 5Ј GGGGTACCGGCTCTTTGATAGAGCTG 3Ј; WPRB, 5Ј GGGGATCCTG CAGCACTTGCACAGCTTC 3Ј) with the B. subtilis 168 chromosomal DNA as template. A KpnI site and a BamHI site were introduced to the 5Ј end and the 3Ј end of the amplified fragment, respectively. Insertion of this fragment into the KpnI and BamHI sites in the polylinker region of pBS generated pBS-WPRA. wprA in pBS-WPRA was disrupted by a double digestion with BglII and EcoRV. This resulted in the deletion of a 465-bp fragment encoding part of WprA. The BglII site of the BglII-EcoRV-digested vector was converted to a blunt end by a fill-in reaction. A 1.5-kb blunt-ended fragment carrying the hygromycin resistance gene (55) was then inserted to the BglII (filled-in)-EcoRV-digested pBS-WPRA to generate p⌬WPRA. This vector which has a unique SphI site in the polylinker region of the parental Bluescript vector was linearized by a SphI digestion and transformed to WB700N to generate WB800 ( Table 1) . Disruption of chromosomal wprA was confirmed by a colony PCR method (52) using Taq DNA polymerase (Amersham Pharmacia Biotech, Baie d'Urfe, Canada). WB800HM was constructed using the same approach for the construction of WB700NHM.
Production and affinity purification of MH-1 SCA. Plasmid pEPP (51) is a B. subtilis vector that allows overproduction of PrsA, an extracytoplasmic molecular chaperone (24, 25, 46) . WB800HM[pMH-1, pEPP] was cultivated in super-rich medium containing kanamycin (10 g/ml), erythromycin (5 g/ml), and lincomycin (5 g/ml) for 6 to 8 h at 37°C. Culture supernatant was separated from the cells by centrifugation at 8,000 ϫ g for 15 min and passed through a 0.22-mpore-size Millipore filter. MH-1 SCA in the filtrate was affinity purified using protein L-agarose (Pierce) according to the manufacturer's instructions. Eluted fractions containing MH-1 SCA (as verified by sodium dodecyl sulfate [SDS]-polyacrylamide gel electrophoresis) were pooled and concentrated by ultrafiltration device (Millipore), and the buffer was changed to 0.05 M sodium phosphate and 0.01 M sodium chloride (pH 6.8). MH-1 SCA was further purified from dimeric and other oligomeric forms by size exclusion chromatography on a Bio-Prep SE-100/17 column (Bio-Rad) calibrated with the gel filtration standard (Bio-Rad) using a Bio-Rad biologic high-resolution protein chromatography system. Eluted fractions were analyzed by SDS-polyacrylamide gel electrophoresis. Fractions containing MH-1 SCA in the monomeric form were pooled and concentrated by ultrafiltration. Purity of the MH-1 SCA was further verified by SDS-polyacrylamide gel electrophoresis followed by staining of the gel with Coomassie blue. Purified MH-1 SCA was quantified spectrophotometrically at 280 nm by using a molar extinction coefficient of 56,140 M Ϫ1 cm Ϫ1 (15) . Immunospecificity study by ELISA. The immunospecificity of MH-1 SCA to fibrinogen, non-cross-linked fibrin and cross-linked fibrin was assessed using standard ELISA protocols based on the method described by Gargan et al. (14) with modifications. Human fibrinogen (Sigma) was coated at 5 g/well onto the surface of a microtiter plate (Falcon PRO-BIND polystyrene plate; Becton Dickinson). Cross-linked fibrin was formed by incubation with 100 l of thrombin (10 NIH units/ml) in Tris-buffered saline (pH 7.4) containing 10 mM CaCl 2 and 7 mM cysteine for 1 h at 37°C. Non-cross-linked fibrin was formed in a similar manner except that 12.5 mM EDTA was used in place of CaCl 2 . Nonspecific sites were blocked by adding, to each well, 200 l of bovine serum albumin (3%) in PBST (0.1 M sodium phosphate, 0.15 M sodium chloride, pH 7.2; 0.1% Tween 20) . Binding of MH-1 SCA to fibrinogen or fibrin was carried out in a final volume of 100 l for 3 h at room temperature. Horseradish peroxidase-conjugated protein L (protein L-HRP; ACTIgen) was used as the detection agent. The amount of protein L-HRP that was bound was assessed using 1-Step ABTS (Pierce) as the HRP substrate. The rate of color development was monitored at 405 nm by using a microplate reader (CERES 900; Bio-Tek Instruments, Inc.).
Dissociation constant determination of MH-1 SCA. The dissociation constants of MH-1 SCA for both cross-linked and non-cross-linked fibrin were determined by Scatchard analysis following standard ELISA protocols. Immobilized fibrin was prepared as described above. Bovine serum albumin (3% in PBST) was used as the blocking agent. The concentrations of purified monomeric MH-1 SCA used in this study ranged from 0 to 6 g/ml. The binding conditions were the same as those described above. After three washes with wash buffer (PBST) to remove the unbound MH-1 SCA, the amount of MH-1 SCA bound to fibrin at a particular MH-1 SCA concentration was determined in reference to a MH-1 SCA standard curve. This curve was generated by coating known amounts of MH-1 SCA directly onto a Falcon PRO-BIND plate and quantification of bound MH-1 SCA by protein L-HRP. Three independent experiments were carried out Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry. Purified MH-1 SCA fragment was prepared in 5 mM ammonium acetate, pH 7.5, at a concentration of 10 pmol/l for molecular mass determination using a Perseptive Biosystems (Framingham, Mass.) Voyager-DE STR mass spectrometer calibrated with myoglobin (m/z 16952) and its dimer (m/z 33904). This instrument was operated in the linear mode, and the acquisition range was 3,000 to 40,000 Da. This analysis was performed at the National Research Council in Saskatchewan, Canada.
Other methods. Vent DNA polymerase (New England BioLabs) was used for all DNA amplification reactions. The sequences of all PCR products were confirmed to be free of PCR errors by nucleotide sequencing based on the dideoxy method using a T7 sequencing kit from Amersham Pharmacia Biotech. SDSpolyacrylamide gel electrophoresis followed standard procedure based on the Laemmli system. Western blotting was done on a nitrocellulose membrane using protein L-HRP (ACTIgen) as the probing agent and 4-chloro-1-naphthol (BioRad) as the color development agent. N-terminal sequencing of secreted MH-1 SCA transblotted to polyvinylidene difluoride (PVDF) membrane (31) was performed by the protein sequencing unit at the University of British Columbia. The production yield of MH-1 SCA in the culture supernatant was quantified using the approach previously described (51).
RESULTS AND DISCUSSION
Design and construction of structural gene encoding MH-1 SCA. The structural gene of the MH-1 SCA fragment was assembled by generating V L , linker, and V H sequences as individual modules (Fig. 1) . Although it is quite common to have V H at the N-terminal position in many SCA constructs, it has been reported in several cases that the presence of V H at the N-terminal position can severely affect both the production yield and biological activities of SCA fragments (2, 4, 7, 45) . Either mistranslation (32) or interference by the presence of a positively charged residue at the N terminus of V H (4) has been suggested to account for some of these observations. Therefore, the variable domains of MH-1 SCA were arranged in the order of V L -linker-V H . Since the first four (DIVL) and three (QVQ) amino acid residues at the N-terminal conserved framework regions of light and heavy chain variable domains, respectively, were missing in the original MH-1 SCA template, these residues were reintroduced back to the B. subtilis version of MH-1 SCA at the nucleotide level by PCR. A 19-amino-acid linker (PNGASESGSAPDTSSAPGS) with a nonrepetitive sequence was designed based on modifications of linker sequences reported by Hennecke et al. (17) . Proline residues located close to the two ends introduce turns to link the variable domains while internal proline and glycine help generate random flexible structure in the linker region. Polar (Ser and Thr) and negatively charged (Asp and Glu) residues were introduced to increase the hydrophilicity of the linker. Lysine residues were avoided because residual proteases from the protease-deficient B. subtilis WB700 strain cleave lysine-rich linker sequences efficiently (Q. Lian and S.-L. Wong, unpublished data). Since SCA fragments with linker sequences shorter than 12 to 15 amino acids have a tendency to form oligomers (12) , the linker sequence used in this study was extended from the traditional 15 amino acids to 19 amino acids. This version of MH-1 SCA fragment was inserted to pWB980 (50) to generate pMH-1 (Fig. 1) . The P43 promoter and the B. subtilis levansucrase signal sequence in the vector were applied to mediate the transcription and secretion processes.
Construction of B. subtilis WB700NHM and its effect on MH-1 SCA production. We have developed a new seven-extracellular-protease-deficient B. subtilis strain, WB700N (Table  1) , for secretory production of foreign proteins (55) . This strain was initially used as the expression host for MH-1 SCA production. To our surprise, analysis of both the culture supernatant and intracellular fraction revealed failure of WB700N[pMH-1] to produce a detectable level of MH-1 SCA fragments (data not shown). This result is very different from the case of secretory production of an anti-digoxin SCA fragment from a six-extracellular-protease-deficient B. subtilis strain, WB600B (51) (52) (53) . In that study, the anti-digoxin SCA fragment was found to be secreted into the culture medium up to 5 mg/liter although a high percentage of the SCA fragments synthesized were accumulated in the cytoplasm as inclusion bodies. To determine whether enhanced coproduction of molecular chaperones can improve the production of MH-1 SCA, a WB700NHM strain was constructed to overproduce the intracellular molecular chaperones which include GroES/GroEL and DnaK/DnaJ/GrpE. Increased production of intracellular molecular chaperones is achieved by the inactivation of the chromosomal repressor gene (hrcA) which specifically controls the expression of the two operons encoding the intracellular molecular chaperones (56) . WB700NHM was then transformed with pEPP (51), a high-copy-number plasmid carrying prsA which codes for the extracytoplasmic molecular chaperone, PrsA, to generate WB700NHM [pEPP] . Transformation of WB700NHM[pEPP] with pMH-1 generated a strain which showed a low but detectable level of MH-1 SCA (Fig. 2B, lane  3) by Western blot analysis. A degraded form of MH-1 SCA was also observed. The results suggest that coproduced molecular chaperones in WB700NHM[pEPP] can improve MH-1 SCA production although some of the secreted MH-1 SCA molecules can still be degraded.
Effect of wall-bound protease WprA on MH1-SCA produc- (Fig. 2, lane 4) produced MH-1 SCA at a much higher level, in the range of 10 to 15 mg/liter. A single band with an apparent molecular mass of 34 kDa, which is larger than the expected molecular mass of 27 kDa, was detected by Western blot analysis probed with protein L-HRP. It is fairly common that SCA fragments tend to have a slower migration on SDS-polyacrylamide gel (7, 53) . Thus, our data indicate that WprA can significantly affect the stability of MH-1 SCA. This observation is consistent with previous reports which demonstrate that WprA can degrade proteins heterologously expressed in B. subtilis, including staphylokinase (27) and ␣-amylase (44). Intracellular and extracytoplasmic molecular chaperones act in sequential manner to enhance MH-1 SCA production. Although WB800HM[pEPP, pMH-1] conspicuously improved secretory production of MH-1 SCA, it is interesting to note that no MH-1 SCA could be detected in both the culture supernatant ( Fig. 3A and B, lanes 2 ) and the intracellular fraction of WB800[pMH-1] (data not shown). This indicates that coproduction of molecular chaperones also plays an important role in MH-1 SCA production. To determine whether both intracellular and extracytoplasmic molecular chaperones are required for enhanced MH-1 SCA production, production of MH-1 SCA in WB800HM[pMH-1] and WB800[pMH-1, pEPP], respectively, was monitored. As shown in Fig. 3B, even with the coproduction of the extracytoplasmic molecular chaperone PrsA in WB800[pEPP] (lane 4), no detectable MH-1 SCA could be observed in the culture supernatant. Neither was it detected in the intracellular fraction (data not shown). In contrast, coproduction of intracellular molecular chaperones alone (lane 3) could significantly increase the production of MH-1 SCA in the culture supernatant. This demonstrates that intracellular molecular chaperones clearly play a vital role in MH-1 SCA production. Further enhancement of MH-1 SCA production could be observed when WB800HM[pEPP, pMH-1] (lane 5) was used as the expression host. Thus, the extracytoplasmic molecular chaperone, acting in concert with the intracellular molecular chaperones, could also enhance the production of MH-1 SCA. Our data suggest that these molecular chaperones may act in a sequential order, with intracellular molecular chaperones acting in the first stage. These intracellular molecular chaperones may potentially assist MH-1 SCA to adopt loosely folded conformations that are compatible with the secretion apparatus and/or to attain configurations that are less susceptible to intracellular protease degradation. After membrane translocation, the secreted MH-1 SCA is presumably refolded. The rate of protein refolding has been shown to affect the final production yield of a secretory protein (43) . Usually, a higher production yield can be attained for secretory proteins with a higher refolding rate. Although the exact mechanism of the PrsA action is still unknown, homology of PrsA to the parvulin family of peptidyl-prolyl cis-trans isomerases suggests that PrsA may catalyze the cis-trans isomerization of proline residues in secretory proteins (40, 51) . Consistent with this idea, proline cis-trans isomerization can be a rate-limiting step in protein and SCA folding (18, 20, 28) and two conserved proline residues in SCA fragments are in the cis configuration (11, 20, 21) . Slower folding of secreted MH-1 SCA in the presence of limited amounts of PrsA may lead to rapid degradation of the protein by the residual proteases in WB800 (22, 46) . Rapid purification and characterization of secreted MH-1 SCA. Like protein A from Staphylococcus aureus and protein G from groups C and G streptococci, protein L, a cell wall protein from Peptostreptococcus magnus, can recognize and bind to certain antibodies (23) . It binds specifically to the variable domain of light chains in immunoglobulins with high affinity (1, 37) . Most important, this binding does not interfere with the interaction between antibodies and their antigens (48) . MH-1 SCA could be specifically recognized by protein L as shown in Fig. 2 and 3 where HRP-conjugated protein L was used as the probing agent in the Western blot studies. This binding of MH-1 SCA by protein L was applied for the purification of MH-1 SCA. Culture supernatant containing secreted MH-1 SCA was loaded directly to a protein L-agarose column. The bound MH-1 SCA was then eluted from the column using a 0.1 M glycine buffer at pH 2.5 (Fig. 4, lanes 5  and 6) . This approach allows purification of MH-1 SCA to homogeneity in one step. The calculated molecular weight of MH-1 SCA is 27,188. Since MH-1 SCA had an apparent molecular mass of 34 kDa as determined by SDS-PAGE, purified MH-1 SCA was subjected to both N-terminal sequencing and MALDI-TOF mass spectrometry analyses. Sequence determination of the first six amino acid residues from MH-1 SCA was found to be DIVLTQ, which matches exactly that of the expected mature light chain sequence of MH-1. This demonstrates that the B. subtilis levansucrase signal sequence was properly processed. Through the MALDI-TOF mass spectrometry study, the molecular mass of MH-1 SCA was determined to be 27,185 Da which is in close agreement with the calculated value.
MH-1 SCA retains comparable specificity and affinity as MH-1 MAb. It has been well established that the length of the linker can greatly affect the oligomeric state of an SCA (3, 12, 26) . Even with a linker of 15 amino acid residues or longer, a low percentage of SCA can exist in a dimeric or oligomeric form. Presence of these oligomeric forms can contribute to an increase in the apparent affinity of these molecules for their antigen (3, 7, 19) . To avoid this complication, the affinitypurified MH-1 SCA fragments were passed through a gel filtration column to separate monomeric MH-1 SCA from other dimeric and oligomeric MH-1 SCA fragments. All functional characterizations of MH-1 SCA were performed with these purified monomeric MH-1 SCA fragments. MH-1 MAb has been shown to bind selectively to fibrin but not to fibrinogen (14) . It also binds to cross-linked fibrin better than non-cross- (Fig. 5B) . Even at high concentrations, MH-1 SCA retained a 13-fold discrimination between fibrin and fibrinogen. It also bound cross-linked fibrin better than the non-cross-linked form.
To determine the binding constant of MH-1 SCA towards fibrin, binding of MH-1 SCA at different concentrations to immobilized fibrin was monitored. After extensive washings to remove the unbound MH-1 SCA, the amounts of the bound MH-1 SCA fragments were quantified using HRP-conjugated protein L. The dissociation constants were determined by the Scatchard plot analyses. In three independent analyses, the dissociation constant of MH-1 SCA to cross-linked fibrin was determined to be 1.37 ϫ 10 Ϫ9 Ϯ 0.72 ϫ 10 Ϫ9 M. This represents approximately a twofold decrease in affinity (14) in comparison with that of the parental MH-1 MAb (K d ϭ 6.7 ϫ 10 Ϫ10 M). It is fairly common for SCA fragments to have a lower affinity (by two-to threefold) since SCA fragment is monovalent (9, 10, 34) . The K d of MH-1 SCA to non-crosslinked fibrin was found to be 6.4 ϫ 10 Ϫ9 M. The results indicate that MH-1 SCA retains similar properties as MH-1 MAb and can be used as a potential fibrin targeting agent.
Significance of the engineered B. subtilis system for SCA production. Different SCAs have different properties that result in a lower production yield for these proteins. In the case of the 26-10 antidigoxin SCA fragment, it tends to aggregate and the rate of inclusion body formation is even faster than the rate of secretion (51) . Consequently, inclusion bodies formed inside the cell represents 60% of the total antibody produced by the cell. In contrast, instead of forming inclusion bodies, the anti-fibrin MH-1 SCA fragment synthesized from WB700N is not even detectable in both extracellular and intracellular fractions, presumably because of its slow folding and sensitivity to proteases. The engineered WB800HM[pEPP] strain provides a solution to address all these situations. In the case of the anti-digoxin SCA fragment, even WB600BHM[pEPP] is sufficient to reduce the inclusion bodies down to 6% and to produce functional anti-digoxin SCA to 15 mg/liter (51) . By addressing the two major concerns, protein folding and degradation by extracellular and wall-bound proteases, in B. subtilis protein secretion (5), this engineered WB800HM[pEPP] system can potentially be applied to produce not only SCA fragments but also other secretory proteins, especially those with folding and protease sensitivity problems. Although SCA fragments have been produced successfully from various expression systems including gram-positive and gram-negative bacteria, yeast (Saccharomyces, Schizosaccharomyces, and Pichia), filamentous fungi (Trichoderma reesei), insect, plant, and mammalian cells, the production yield of these fragments in their functional state can vary significantly (7) . It is difficult to predict which system works the best for the production of a particular SCA fragment. The improvement of the 
